Funding:

ImStem Biotechnology

Description

The purpose of this research is to determine the safety, tolerability, efficacy, and optimal dose regimen of an investigational human embryonic stem cell derived (hESC) mesenchymal stem cell (MSC) product to treat MS called IMS001.Taking part in this research will last for up to 5 years/61 months, consisting of a 1-month Screening Phase, a 12-month Treatment Phase, and a 48-month or more Long-term Follow-up Phase. The study will involve clinic visits that include clinical exams, electrocardiograms, MRI, blood draws, and on one or two visits, infusion treatment. This is an open-label study, which means you and the study doctor will know which group you are in and therefore which dose of study drug you are receiving.

Contact information:
Contact Name: Sue Griffiths/Tammy Hoyt
Phone:801-408-5700
Email:sgriffiths@rmmsc.com thoyt@rmmsc.com